A biomarker is a biological characteristic measured and evaluated as a maker of pathological processes or a response to a therapeutic intervention. According to Marketstack, the Global Biomarker Technologies Market is expected to grow considerably during the forecasted period. Factors such as the high prevalence of cancer and cardiac problems and biomarker advancements are expected to drive the Biomarker Technologies Market in the forecasted period. Further, the growing applications of biomarkers in personalized medicine and the increasing utility of biomarkers in the diagnostic practice are expected to drive the Biomarker Technologies Market in the forecasted period. Furthermore, the growing number of geriatric people worldwide and rising disposable revenue demanding effective healthcare services are expected to drive the Biomarker Technologies Market in the forecasted period. However, low cost-benefit ratios, high capital investments, unfavourable satisfied policies, and technical issues associated with sample and storage are expected to hamper the development of the biomarker technologies market in the forecasted period.

Biomarkers are extensively used to diagnose diseases such as cancer, infectious diseases, autoimmune diseases, etc.

The elevating incidence of different types of cancers is expected to boost demand for cancer biomarkers. Biomarkers are essential in combating the increasing burden of cancer by enabling early detection, precise diagnosis, treatment selection, and disease monitoring. Biomarkers can screen for and detect cancer early, allowing prompt treatment while the condition is more curable. Blood tests and liquid biopsies are two examples of biomarker-based screening techniques that can identify the presence of particular biomarkers linked to specific malignancies. In addition, biomarkers can forecast how likely a patient will acknowledge a given therapy or treatment. By analyzing biomarkers, healthcare professionals can identify patients more likely to benefit from a particular therapy approach, such as targeted medicines or immunotherapies. The future burden of cancer is expected to be even more significant due to the increasing prevalence of unhealthy food habits, smoking, and physical inactivity, among others. Biomarkers can indicate a variety of disease characteristics. Cancer is a disease developed through a multi-stage carcinogenesis process involving numerous molecular pathway events, creating a hurdle in prognosis, diagnosis, and therapy. Due to the complicated nature of cancer, a single marker is not helpful. Investment in biomarker research has increased due to scientific developments, improved knowledge of biomarker utility, the potential for therapeutic effect, and supporting regulatory frameworks. Pharmaceutical businesses, biotechnology companies, research institutes, and governmental organizations have all made significant investments to improve patient outcomes and lower healthcare costs. Moreover, each type of cancer varies from others in molecular profile. The discovery of new biomarkers offers new opportunities for driving therapeutic strategies designed to reverse dysregulation in cancer. Thus, the surging prevalence of cancer will propel biomarker technologies and, in turn, the growth of the global market.

North America currently dominates the market for biomarkers and is expected to continue its stronghold for a few more years. In North America, the United States holds the most significant market share. The number of USFDA-approved drug labels containing information on molecular biomarkers has increased dramatically over the last decade. Moreover, the increasing burden of chronic diseases in the United States generates demand for effective and specific biomarkers. In the growing "personalized medicine" field, biomarkers are becoming an increasingly significant factor. They help choose the correct dose and prognosis prediction. In addition, they might help identify therapeutic and unfavourable reactions and for patient classification based on efficacy or safety forecasts. "Providing the right treatment to the right patient, at the right dose, at the right time," biomarkers are crucial instruments for selecting suitable patients for treatment with certain pharmaceuticals. Researchers now understand more about the underlying molecular mechanisms of disease due to advances in genomics and proteomics, which have also made it easier to identify biomarkers with clinical significance. The search for biomarkers has been transformed by genomics and proteomics technology. It is now possible to affordably sequence entire genomes or particular sections of interest using high-throughput sequencing techniques like next-generation sequencing (NGS). As a result, new potential biomarkers have been discovered. This has made identifying genetic variants, mutations, and modifications linked to diseases easier.

The market key players are BIO-RAD LABORATORIES, INC., Shimadzu Corporation, PerkinElmer INC., LI-COR, Inc., and Thermo Fisher Scientific, Inc.

In February 2022, the Foundation for the NIH Biomarkers Consortium launched a new project, "Neurofilament as a Fluid Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD)", that will identify the best blood tests to calculate a protein that is instrumental in the detection of rare neurodegenerative diseases.

In February 2022, OncoDNA, a genomic and therapeutic company, launched the OncoDEEP kit. The kit provides a complete workflow solution that enables laboratories with NGS capabilities to perform comprehensive biomarker testing, provide robust data analysis, and support oncologists with the most effective and personalized treatments for their cancer patients.

Global Biomarker Technologies Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Biomarker Technologies Market by segmenting based on Product (Consumables and Instruments), Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunoassay, and Others), and Application (Drug Discovery, Diagnostics, and Personalized Medicine), and Indication (Cancer, Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders, and Others), and Geography (Asia-Pacific, North America, Europe, South America, and Middle East & Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers emerging market trends, development, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.